Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IRCCS National Neurological Institute "C. Mondino" Foundation
The main study is a randomized controlled trial enrolling patients with chronic migraine and medication overuse (MoH). Participants will undergo a standardized in-hospital detoxification protocol and will be randomly assigned to one of three parallel groups to receive either sham stimulation, active repetitive transcranial magnetic stimulation (rTMS) applied over the motor cortex face representation, or active rTMS applied over the motor cortex forearm representation. Stimulation will be delivered for five consecutive days.
Clinical, sensory (Quantitative Sensory Testing, QST), and biochemical measures (plasma glutamate, serotonin, and calcitonin gene-related peptide, CGRP) will be collected at baseline and during follow-up.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of chronic migraine and medication overuse according to ICHD-3 criteria
Ability to provide written informed consent
You may not be if
Major psychiatric disorders (e.g., major depressive disorder)
Changes in preventive migraine therapy within the last 3 months
Ongoing treatment with monoclonal antibodies for migraine prevention
Other significant neurological or systemic diseases
Pregnancy
Contraindications to transcranial magnetic stimulation (for main study participants)